New Zealand markets closed

Bio-Techne Corporation (TECH)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
83.81+0.97 (+1.16%)
At close: 04:00PM EDT
84.00 +0.19 (+0.23%)
After hours: 04:53PM EDT

Bio-Techne Corporation

614 McKinley Place N.E.
Minneapolis, MN 55413
United States
612 379 8854

Full-time employees3,200

Key executives

NameTitlePayExercisedYear born
Mr. Kim KeldermanCEO, President & Director845.71k126.84k1968
Mr. James T. HippelExecutive VP of Finance & CFO691.78kN/A1971
Mr. Shane BohnenSenior VP, General Counsel & Corporate Secretary353.6kN/A1975
Mr. Charles R. KummethSenior Advisor & Director1.26M48.58M1960
Mr. William A. GeistPresident of Protein Sciences Segment533.67kN/A1970
Dr. Gary J. Latham Ph.D.VP & CTON/AN/AN/A
David ClairSenior Director of Investor Relations & Corporate DevelopmentN/AN/AN/A
Mr. Gerry AndrosVice President of Sales and MarketingN/AN/AN/A
Mr. Robert M. GavinVice President of Corporate Development724.51kN/A1968
Mr. Luca CicchettiManaging DirectorN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Corporate governance

Bio-Techne Corporation’s ISS governance QualityScore as of 1 May 2024 is 10. The pillar scores are Audit: 10; Board: 4; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.